These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 34189655)
41. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System. Qi P; Bu R; Zhang H; Yin J; Chen J; Zhang A; Gou J; Yin T; Zhang Y; He H; Wang P; Tang X; Wang Y Mol Pharm; 2019 Aug; 16(8):3502-3513. PubMed ID: 31251642 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Rafiei P; Haddadi A Pharm Nanotechnol; 2017; 5(1):3-23. PubMed ID: 28948907 [TBL] [Abstract][Full Text] [Related]
43. Tunable sustained release drug delivery system based on mononuclear aqueous core-polymer shell microcapsules. Abulateefeh SR; Alkawareek MY; Alkilany AM Int J Pharm; 2019 Mar; 558():291-298. PubMed ID: 30641178 [TBL] [Abstract][Full Text] [Related]
44. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles. Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911 [TBL] [Abstract][Full Text] [Related]
45. The role of a drug-loaded poly (lactic co-glycolic acid) (PLGA) copolymer stent in the treatment of ovarian cancer. Wang Y; Qiao X; Yang X; Yuan M; Xian S; Zhang L; Yang D; Liu S; Dai F; Tan Z; Cheng Y Cancer Biol Med; 2020 Feb; 17(1):237-250. PubMed ID: 32296591 [No Abstract] [Full Text] [Related]
46. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. Zhang C; Yang L; Wan F; Bera H; Cun D; Rantanen J; Yang M Int J Pharm; 2020 Jul; 585():119441. PubMed ID: 32442645 [TBL] [Abstract][Full Text] [Related]
47. Dry fabrication of poly(dl-lactide-co-glycolide) microspheres incorporating a medium molecular drug by a ball mill method. Matsumoto A; Murakami M Drug Discov Ther; 2021 Mar; 15(1):20-27. PubMed ID: 33627576 [TBL] [Abstract][Full Text] [Related]
48. FDA critical path initiatives: opportunities for generic drug development. Lionberger RA AAPS J; 2008; 10(1):103-9. PubMed ID: 18446510 [TBL] [Abstract][Full Text] [Related]
49. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Jain RA Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295 [TBL] [Abstract][Full Text] [Related]
50. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652 [TBL] [Abstract][Full Text] [Related]
51. Effect of polymer source variation on the properties and performance of risperidone microspheres. Wan B; Bao Q; Zou Y; Wang Y; Burgess DJ Int J Pharm; 2021 Dec; 610():121265. PubMed ID: 34748813 [TBL] [Abstract][Full Text] [Related]
52. Sodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis. Cevher E; Orhan Z; Sensoy D; Ahiskali R; Kan PL; Sağirli O; Mülazimoğlu L J Microencapsul; 2007 Sep; 24(6):577-95. PubMed ID: 17654177 [TBL] [Abstract][Full Text] [Related]
53. Generic drug device combination products: Regulatory and scientific considerations. Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118 [TBL] [Abstract][Full Text] [Related]
54. PLGA: From a classic drug carrier to a novel therapeutic activity contributor. Chereddy KK; Payen VL; Préat V J Control Release; 2018 Nov; 289():10-13. PubMed ID: 30244137 [TBL] [Abstract][Full Text] [Related]
55. Incorporation of fast dissolving glucose porogens and poly(lactic-co-glycolic acid) microparticles within calcium phosphate cements for bone tissue regeneration. Smith BT; Lu A; Watson E; Santoro M; Melchiorri AJ; Grosfeld EC; van den Beucken JJJP; Jansen JA; Scott DW; Fisher JP; Mikos AG Acta Biomater; 2018 Sep; 78():341-350. PubMed ID: 30075321 [TBL] [Abstract][Full Text] [Related]
56. Accelerated in vitro release testing method for a long-acting peptide-PLGA formulation. Goel M; Leung D; Famili A; Chang D; Nayak P; Al-Sayah M Eur J Pharm Biopharm; 2021 Aug; 165():185-192. PubMed ID: 33992753 [TBL] [Abstract][Full Text] [Related]
57. Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres. Ghassemi AH; van Steenbergen MJ; Barendregt A; Talsma H; Kok RJ; van Nostrum CF; Crommelin DJ; Hennink WE Pharm Res; 2012 Jan; 29(1):110-20. PubMed ID: 21744173 [TBL] [Abstract][Full Text] [Related]
58. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Tunçay M; Caliş S; Kaş HS; Ercan MT; Peksoy I; Hincal AA Int J Pharm; 2000 Feb; 195(1-2):179-88. PubMed ID: 10675695 [TBL] [Abstract][Full Text] [Related]